Pharmaceuticals

HIV Drugs Market Forecast: What to Expect by 2029

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The HIV Drugs Market Between 2025 And 2029?

The HIV drugs market has consistently expanded in recent years. It is forecast to rise from $35.33 billion in 2024 to $36.55 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 3.5%. This market’s historical growth is attributable to factors including enhanced government support and initiatives, an increase in healthcare expenditure, greater spending on HIV research and development, a higher incidence of HIV infection, increased public awareness, and economic advancement in emerging markets.

The HIV drugs market is set for consistent expansion over the coming years, with its size predicted to reach ” $41.55 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 3.3%. This projected growth is driven by several factors, including heightened government backing and initiatives, an increase in healthcare expenditure, greater spending on HIV research and development, a rising incidence of HIV infection, increased public awareness, and economic advancement in emerging markets. Significant trends for the forecast period involve investments in 3D bioprinting technology, the introduction of innovative products, the development of multi-class combination treatments for HIV, and engagement in strategic collaborations and agreements.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2834&type=smp

Which Drivers Are Impacting The HIV Drugs Market?

Increased public understanding of HIV disease diagnosis and treatment serves as a significant catalyst for the expansion of the HIV drug market. HIV/AIDS is recognized as a highly chronic illness, and its widespread global prevalence has generated unprecedented awareness about the condition. For instance, in July 2024, the United Nations International Children’s Emergency Fund (UNICEF), a US-based Humanitarian aid organization, published data indicating that in 2023, an estimated 40.0 million people were living with HIV worldwide. Among these, 2.38 million were children aged 0-19. Each day in 2023, approximately 685 children acquired HIV and around 250 children died from AIDS. Therefore, heightened awareness among individuals concerning the diagnosis and treatment of HIV disease acts as a crucial driver for the growth of the HIV drug market.

How Is The HIV Drugs Market Classified Into Different Segments?

The hiv drugs market covered in this report is segmented –

1) By Type: Nucleoside Reverse Transcriptase Inhibitors (NRT’s), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s), Protease Inhibitors, Integrase strand transfer inhibitors (INSTIs), Other Types

2) By Administration: Oral, Parenteral

3) By Application: Hospital Pharmacies, Retail Pharmacies, Other Applications

Subsegments:

1) By Nucleoside Reverse Transcriptase Inhibitors (NRTIs): Zidovudine (AZT), Lamivudine (3TC), Abacavir (ABC), Tenofovir disoproxil fumarate (TDF), Other NRTIs

2) By Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Efavirenz (EFV), Nevirapine (NVP), Etravirine (ETR), Rilpivirine (RPV), Other NNRTIs

3) By Protease Inhibitors (PIs): Ritonavir (RTV), Lopinavir (LPV), Darunavir (DRV), Atazanavir (ATV), Other PIs

4) By Integrase Strand Transfer Inhibitors (INSTIs): Raltegravir (RAL), Dolutegravir (DTG), Bictegravir (BIC), Other INSTIs

5) By Other Types: Entry Inhibitors, Fusion Inhibitors, Combination Therapies

Which Ongoing Trends Are Expected To Shape The HIV Drugs Market Outlook?

Major companies in the HIV drugs market are forging strategic alliances for the manufacturing of Lenacapavir. These collaborations are aimed at accelerating drug development, expanding access to treatments, and strengthening their global market presence. Lenacapavir is recognized as a first-in-class HIV-1 capsid inhibitor, proving effective when used alongside other antiretrovirals and targeting multiple stages of the HIV lifecycle, making it a promising alternative for patients with limited treatment options. As an illustration, in August 2023, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, and Hetero, another India-based pharmaceutical company, entered into a partnership with Gilead Sciences Inc., a US-based biopharmaceutical company. This agreement enables Dr. Reddy’s Laboratories and Hetero to manufacture and distribute the HIV drug lenacapavir in 120 primarily low- and lower-middle-income countries (LMICs). This initiative is designed to broaden availability of this innovative treatment, which is especially beneficial for heavily treatment-experienced patients dealing with multi-drug-resistant HIV.

Who Are The Core Companies Influencing The HIV Drugs Market Landscape?

Major companies operating in the HIV drugs market include Gilead Sciences Inc., Johnson & Johnson, Merck & Co. Inc., Boehringer Ingelheim International GmbH, Cipla, Aurobindo Pharma, AbbVie, Emcure Pharmaceuticals, Micro Labs Limited, Northeast Pharmaceutical Group Co. Ltd, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd, Strides Arcolab Limited, Hetero Labs Limited, Shanghai Desano Bio-pharmaceutical Co., Anhui Biochem Biopharmaceutical Co. Ltd., China’s National Health Commission (NHC), Shanghai Xinxing Medicine Co. Ltd., China Meheco Xinxing Pharma Co. Ltd., CytoDyn Inc., Janssen Pharmaceutical, Bavarian Nordic, Roche Laboratories, Pharmstandard, Pharmasyntez, R-Pharm, Alium, ChemRar Group, Gritstone Oncology, Enzolytics Inc., BioClonetics Immunotherapeutics Inc., Dewpoint Therapeutics, Lyndra Therapeutics, Mylan N.V., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Teva Canada, ViiV Healthcare Canada, GSK, Abbott Laboratories, Aspen Pharmacare Limited, Pharmacare Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/hiv-drug-global-market-report

What Are The Key Regional Factors Influencing The HIV Drugs Market Growth?

North America was the largest region in the HIV drugs market share in 2024. Middle East is expected to be the largest growing region in the global HIV drug market during the forecast period. The regions covered in the HIV drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The HIV Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=2834&type=smp

Browse Through More Reports Similar to the Global HIV Drugs Market 2025, By The Business Research Company

Pharmaceuticals Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmaceuticals-global-market-report

Drugs For Hormonal Replacement Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/drugs-for-hormonal-replacement-therapy-global-market-report

Hormonal Contraceptives Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hormonal-contraceptives-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795